Kamada

Company Overview

Snapshot

Founded in December 1990 by David Tsur, Kamada operates with 201–500 employees. The company has raised a total of $150 million across 7 funding rounds from 2 investors.

Business overview

Kamada is a plasma-derived protein therapeutics company that leverages its proprietary platform technology to extract and purify proteins from human plasma. The company's commercial portfolio includes two FDA-approved products: GLASSIA, for Alpha-1 Antitrypsin (AAT) deficiency, and KEDRAB, a rabies immune globulin. Kamada also markets four additional plasma-derived pharmaceutical products globally and has a late-stage clinical pipeline focusing on inhaled AAT, intravenous AAT for type 1 diabetes and GvHD, and lung transplant rejection prevention. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, serving healthcare providers and pharmaceutical markets.

Strategic signal

In November 2021, Kamada announced a strategic transformational transaction aimed at positioning the company as a global leader in the plasma-derived hyperimmune market through the acquisition of a portfolio of four FDA-approved commercial products. This move signals a significant expansion of Kamada's product offerings and market reach, indicating a strong growth trajectory and strategic intent to consolidate its position in a specialized therapeutic area.

Company Intelligence Q&A

What was a significant strategic move by Kamada in late 2021?

In November 2021, Kamada announced a strategic transformational transaction to acquire a portfolio of four FDA-approved commercial products, aiming to become a global leader in the plasma-derived hyperimmune market.

When did Kamada expand its plasma collection operations in Texas?

In September 2024, Kamada announced the expansion of its plasma collection operations in Texas with the opening of a new site in Houston.

What is Kamada's current status on the stock exchanges?

Kamada went public on TASE in September 2005 and on NASDAQ in June 2008.

What was a key operational update regarding Kamada's Israeli operations?

In October 2023, Kamada provided a corporate update on its Israel operations.